A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
Status:
Withdrawn
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
To establish the safety and efficacy of HTL0018318 compared with placebo when administered
once daily for 12 weeks to patients with dementia with Lewy bodies.